SCHEMBL12918267

SCHEMBL12918267

COc1cc(Nc2nc3n(n2)CCCCC3c2ccc(Cl)cc2)ccc1-c1cnn(C)c1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 15/20 0.60
▸ PSEN2 P49810 15/20 0.60
▸ APH1B Q8WW43 15/20 0.60
▸ NCSTN Q92542 15/20 0.60
▸ APH1A Q96BI3 15/20 0.60
▸ PSENEN Q9NZ42 15/20 0.60
▸ APP P05067 5/20 0.44
▸ TYRO3 Q06418 2/20 0.39
▸ AAK1 Q2M2I8 1/20 0.39
▸ AXL P30530 1/20 0.37
▸ CCNA2 P20248 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ TTK P33981 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ PTK2 Q05397 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL964389 0.93 PSEN1 (0.55) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL15062311 0.92 PSEN1 (0.60) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL12918266 0.80 PSEN1 (0.74) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL963472 0.78 PSEN1 (0.95) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL136503 0.74 PSEN1 (0.76) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL964276 0.74 PSEN1 (0.95) PSEN1PSEN2APH1BNCSTNAPH1A
Trifluoroacetic Acid SCHEMBL961322 0.74 PSEN1 (0.67) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2227350 0.74 PSEN1 (0.79) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL965228 0.74 PSEN1 (0.72) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL961703 0.74 PSEN1 (0.84) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379553-B1 BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2013-06-26 — — EP claimed
US-8349880-B2 Bicyclic compounds for the reduction of beta-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-08 — — US disclosed
US-8349880-B2 Bicyclic compounds for the reduction of beta-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-08 — — US disclosed
US-20110015175-A1 Bicyclic Compounds for the Reduction of Beta-Amyloid Production BRISTOL-MYERS SQUIBB COMPANY 2011-01-20 — — US disclosed
US-20110015175-A1 Bicyclic Compounds for the Reduction of Beta-Amyloid Production BRISTOL-MYERS SQUIBB COMPANY 2011-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015175-A1 Bicyclic Compounds for the Reduction of Beta-Amyloid Production APP, BACE1, APBA1 PSEN1 6/4885PSEN2 7/4885APH1B 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback